SUMMARY
Tenoxicam is a relatively new thienothiazine derivative of the oxicam class of non-steroidal antiinflammatory drugs (NSAID). Its analgesic and antiinflammatory efficacy and frequency of side effects compare favourably with those of other NSAID when used orally for long term treatment of rheumatological conditions [2] . NSAID are used widely for postoperative analgesia [3] ; for this application, tenoxicam has the advantages of i.v. formulation and a long half-life of plasma concentration (60-75 h) [2] .
We have used patient-controlled analgesia (PCA) [4] , in a prospective, placebo-controlled, doubleblind study, to assess the analgesic efficacy of tenoxicam used as a single i.v. dose after operation.
METHODS AND RESULTS
We decided that an analgesic advantage sufficient to manifest at the 5 % significance level with a sample size of 10 would be relevant to our clinical practice. Thus if we nominated a reduction in papaveretum consumption of 1.5 mg h" 1 or more as indicative of clinically useful analgesic efficacy for tenoxicam, the power of a one-tailed t test to distinguish this would be greater than 80 % (given P < 0.05: estimating placebo group mean = 5 mg h" 1 and sample SD = 25 % of the mean).
After Ethics Committee approval, informed consent was obtained from 20 patients, older than 18 yr, undergoing lateral thoracotomy. One (who received placebo) was subsequently unable to manage the PCA device and was withdrawn. Exclusion criteria were: hypersensitivity to NSAID; history of peptic ulceration, gastrointestinal bleeding or any bleeding disorder; presence of severe renal (creatinine > 0.2 mg ml" 1 ), hepatic, cardiac or haemopoietic disease; any possibility of pregnancy; and use of NSAID, opioids, diuretics or angiotensin converting enzyme inhibitors in the 24 h preceding surgery.
All patients were premedicated with diazepam and famotidine. Anaesthesia was induced with thiopentone and maintained with fentanyl (1 ug kg" 1 initially, and then up to 0.5 ug kg" 1 half-hourly), nitrous oxide and isoflurane or halothane in oxygen. No regional anaesthetic techniques, nerve blocks, other NSAID or other analgesics were used. Either tenoxicam 20 mg or placebo was administered i.v. at the beginning of chest closure from unidentifiable, sequentially numbered ampoules, randomized in blocks of 10. In the recovery room, analgesia was commenced with a Bard PCA pump programmed (in accordance with our then normal clinical practice) to deliver papaveretum with a loading dose of 0.075 mg kg" 1 (maximum 6 mg), a background infusion of 0.025 mg kg" 1 h" 1 (maximum 2 mg h" 1 ), boluses of 0.025 mg kg" 1 (maximum 2 mg), a "lockout" interval between boluses of 5 min and an hourly limit of 0.15 mg kg" 1 (maximum 12 mg). Papaveretum consumption was measured hourly; all other assessments were made at 1, 2, 4, 8, 12 and 24 h.
Operations undertaken in the tenoxicam group included removal of a recurrent liposarcoma; removal of a metastatic mediastinal teratoma; repair of a hiatus hernia; five lobectomies; two pneumonectomies. In the placebo group there were seven lobectomies and two pneumonectomies.
Mean age (62.5 yr, range 48-74 yr) and weight (69.0 (SD 15.3) kg) of patients receiving tenoxicam did not differ significantly from the mean age (65 yr (range 43-76 yr) and weight (79 (17.3) kg) of those receiving placebo (two-tailed t test: f > >0.18). However, only one of the placebo group was female, in contrast to five of the tenoxicam group.
The pain scores (on unmarked 100-mm visual analogue scales) reported by the two groups were I.V. TENOXICAM FOR ANALGESIA AFTER THORACOTOMY , respectively (one-tailed t tests: P = 0.05 and P = 0.07). In contrast, the tenoxicam group used 0.4 mg h" 1 (12.5 %) more papaveretum than the placebo group from 12 to 24 h (ns). Repeated measures analysis of variance (RMANOVA) [5] (using " Statgraphics " Statistical Graphics System by Statistical Graphics Corporation, Version 4.0, on an Intel 8088 based microprocessor running Microsoft's "MS-DOS" Version 3.2), across die papaveretum consumption (non-cumulative) for the three time periods 0-4, 4-8 and 8-12 h confirmed that die difference between groups over die first 12 h was significant (F ratio = 8.4; P < 0.01). After subtraction of the papaveretum delivered by continuous infusion, the difference remained significant (P = 0.01). There was no significant difference in papaveretum consumption between the six females and the 13 males in the study.
There were no important differences between tenoxicam and placebo groups for vomiting (two vs two), moderate nausea (two vs one), mild nausea (six vs five), moderate sedation (five vs four) or mild sedation (four vs four). No patient in either group experienced severe sedation, a ventilatory frequency less than 10 b.p.m. or any alteration in heart rate or arterial pressure requiring intervention.
The preoperative values of haemoglobin and creatinine were compared with die worst value in die 5 days after surgery. Mean decrease in haemoglobin concentration was 14.0 (9.1) g litre" 1 in die tenoxicam group and 14.5 (7.0) g litre" 1 in die placebo group (one-tailed paired t test: P < 0.01 in each case): diere was no significant difference between groups. Mean decrease in creatinine clearance (estimated from creatinine by die Cockcroft Gault correction for age, weight and sex) after operation was smaller in the tenoxicam group (0.03 (0.23) ml s' 1 ) (ns). There were no odier adverse reactions to NSAID.
COMMENT
Consumption of opioid with postoperative PCA may be influenced by many factors [4] ; in diis study, because die placebo group had more males and a greater mean weight, the average background infusion and bolus size were larger dian in die tenoxicam group and this may have contributed to die result. However, neidier die weight difference between groups nor the difference in opioid consumption between males and females overall was significant, and (by contrast) the difference between subjects and controls remained significant even after subtraction of die background infusion from die total papaveretum consumed. Furthermore, the reduced opioid consumption in die tenoxicam group occurred early (0-12 h) and then disappeared ( fig. 1 ), so that from 12 to 24 h the tenoxicam patients actually used slightly more papaveretum than die controls. This fits well with a drug effect, which might have worn off widi time, but cannot be attributed to die odier factors, which were constant.
When using a drug widi a long half-life, it is usual to administer a loading dose. We based our dose of tenoxicam on the only recommendation available, namely diat for long term use in rheumatic conditions. However, a single dose of 20 mg i.v. produces blood concentrations of only 3 ug ml" 1 compared with more dian 10 ug ml" 1 at steady state with 20 mg daily by mouth [6] . This may explain die unexpectedly short duration of effect. For single or initial administration, a larger dose would probably be more appropriate.
One important aim of this study was to provide equally effective analgesia to subjects and controls; success in tiiis virtually precludes the demonstration of any clinical advantage, other dian opioid sparing, for the drug.
The side effects of NSAID are well known and of concern, particularly in high risk patients, but diey must be weighed against die continuing widespread failure to provide adequate analgesia following surgery [7] . We have shown encouraging analgesia after thoracotomy from a single i.v. dose of tenoxicam 20 mg, with no obvious increase in side effects; further studies are now warranted to identify more fully die optimal dose of tenoxicam and its role in die provision of postoperative analgesia.
